Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02192970 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab Against Recurrent Retinal Detachment
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT02192970 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 101 participants.
The verdict
NCT02192970, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.
Interventions
- DRUG Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2015-01-21 |
| Est. Completion | 2019-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02192970
The ClinicalTrials.gov registry entry for NCT02192970 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab is the first listed.
NCT02192970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02192970 about?
NCT02192970 is a clinical study titled "Bevacizumab Against Recurrent Retinal Detachment". The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.
What is the current status of trial NCT02192970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2015-01-21. Estimated completion is 2019-11-11.
What interventions are being tested in trial NCT02192970?
The interventions under investigation include: Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT02192970?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.